



## Movement Disorders 1

130

WFN15-0993

### Movement Disorders 1

#### Heterogeneous determinants of quality of life in different phenotypes of Parkinson's disease

S.M. Fereshtehnejad<sup>a</sup>, M. Shafieesabet<sup>b</sup>, F. Farhadi<sup>b</sup>, H. Hadizadeh<sup>b</sup>, A. Rahmani<sup>b</sup>, N. Naderi<sup>b</sup>, D. Khaefpanah<sup>b</sup>, G.A. Shahidi<sup>c</sup>, A. Delbari<sup>d</sup>, J. Lökk<sup>e</sup> *Clinical Geriatrics NVS, Karolinska Institutet, Stockholm, Sweden;* <sup>b</sup>*Medical Student Research Committee (MSRC), Iran University of Medical Sciences, Tehran, Iran;* <sup>c</sup>*Department of Neurology, Iran University of Medical Sciences, Tehran, Iran;* <sup>d</sup>*Iranian Research Center on Aging, University of Social Welfare and Rehabilitation, Tehran, Iran;* <sup>e</sup>*Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden*

**Background:** Health-related quality of life (HRQoL) is an important outcome in patients with Parkinson's disease (PD). A broad list of motor and non-motor features affect quality of life, however, there is a dearth of information about the complexity of interrelationships between its determinants in different phenotypes.

**Objective:** We aimed to find independent determinates and the best structural model for HRQoL, and investigate the heterogeneity between PD patients with different phenotypes regarding onset-age, progression rate and dominant symptom.

**Patients and methods:** A broad spectrum of demographic, motor and non-motor characteristics were investigated in 157 idiopathic PD patients namely comorbidity profile, nutritional status, UPDRS, psychiatric symptoms, fatigue, psychosocial functioning and PD severity index using Parkinson's Disease Questionnaire-39. Structural equation model and multivariate regressions were applied.

**Results:** Female sex, anxiety, depression and UPDRS-part II scores were the significant independent determinants of PD severity index. A model consisted of global motor, non-motor and co-morbidity components was able to explain 89% of the variance in HRQoL. In older-onset and slow-progression phenotypes, motor domain showed smaller contribution and the majority of its effects was mediated through non-motor features. Comorbidity component was a significant determinant only among older-onset and non-tremor-dominant patients. Fatigue was not a significant indicator of non-motor component to affect quality of life in rapid-progression PD.

**Conclusion:** Our findings showed outstanding heterogeneities in the pattern and determinants of HRQoL in different PD phenotypes, which should be considered during the assessments and developing personalized interventions to improve life quality in PD patients with different prominent features.

doi: [10.1016/j.jns.2015.08.206](https://doi.org/10.1016/j.jns.2015.08.206)

131

WFN15-1037

### Movement Disorders 1

#### Outcome of autosomal recessive early onset Parkinson's disease patients with PINK1 gene-5 year follow-up (2010–2015)

S. Elsadig, A.A. Ahmed. *Department of Medicine, Faculty of Medicine, University of Khartoum, Khartoum, Sudan*

**Background:** In 2009 a new complex homozygous large rearrangement of the pink1 gene in a Sudanese family with early onset Parkinson's disease was reported. The members of this family were followed-up for the last 5 years; we here report their clinical progression, management modalities and outcomes

**Case report:** This family was first seen in 2005 at OPD for adult neurology at Soba University Hospital (one of the Khartoum University hospitals). Four members of the family presented with progressive difficulty in initiating movement, resting tremors and shuffling gait. A provisional diagnosis of early onset Parkinson's disease (EOPD) was made and genetic workup revealed a mutation in the PINK1 gene. Symptoms started as early as 9 years in one patient and at 1–14 years in others. All family members developed motor symptoms including bradykinesia, resting tremors, postural instability and rigidity. Two patients have severe non motor symptoms including depression, cognitive impairment, and sleep disorders. Two patients had severe side effects to levodopa and in spite of being given small frequent doses they are still suffering from severe rigidity and bradykinesia and getting severe dyskinesia at the onset of medication.

**Conclusion and recommendation:** For the last 5 years the patients have shown progression in their symptoms and have started developing impaired cognitive functions. Is there any management option that gives hope for these patients to improve their quality life?

doi: [10.1016/j.jns.2015.08.207](https://doi.org/10.1016/j.jns.2015.08.207)

132

WFN15-1079

### Movement Disorders 1

#### Neuropsychological assessment in a Chilean cohort of patients with Parkinson's disease

M. Vásquez, W. Uslar, H. Farías, C. Juri. *Department of Neurology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile*

**Background:** Cognitive impairment is a great challenge in patients with Parkinson's Disease (PD). We present a neuropsychological assessment in a PD population using a standardized battery based on Movement disorders Society recommendations.

**Patients and methods:** We evaluated extensively different cognitive domains (attention, memory, language, executive functions and processing speed) and depressive symptoms in a prospective cohort of PD patients in control in our center, using a standardized neuropsychological battery.

**Results:** Twenty five patients were included. Age (mean  $\pm$  SD) was  $60.8 \pm 11.7$  years, 28% were females. PD evolution was between 2 and 15 years. Alterations in at least one neuropsychological test were present in 100% of subjects. Dementia was diagnosed in 18% of patients, whereas mild cognitive impairment was present in 36% of the cases. Dementia was present in 60% of those older than 70 years. MoCA test was affected in 80% of cases ( $Z: -2.6 \pm 1.9$ ). AVLT (Episodic auditory verbal memory) was altered in 84% of subjects ( $Z: -3.8 \pm 2.0$ ). BVMT (Visuospatial memory) was affected in 44% of patients ( $Z: -1.4 \pm 0.9$ ). Boston test (semantic memory) was altered in 40 subjects ( $Z: -1.1 \pm 1.2$ ). TMT-A (visual attention) was altered in 32% of cases ( $Z: 0.6 \pm 2.4$ ). Digit Span (Auditive attention) was affected in 32% of patients ( $Z: -0.4 \pm 1.8$ ). SDMT (Processing speed) was altered in 24% of cases ( $Z: -0.4 \pm 1.0$ ). FAS (cognitive alternancy) was affected in 28% of subjects ( $Z: -0.5 \pm 1.4$ ). The tower test of D-KEFS was altered in 20%, ( $Z: -0.5 \pm 1.4$ ). Depressive symptoms were present in 53% of patients.

**Discussion:** We found a high percentage of cognitive alterations in our PD population. Both verbal and visual episodic memory were affected in 50% of patients. As previously reported, older patients were more affected by dementia.

FONDECYT N° 11130534.

doi:10.1016/j.jns.2015.08.208

133

WFN15-1087

Movement Disorders 1

**Impulsivity, but not dopamine agonists, explains severity of impulse control disorders in PD**

J. Marin-Lahoz, J. Pagonabarraga, R. Fernandez-de-Bobadilla, B. Pascual-Sedano, J. Perez-Perez, A. Gironell, J. Kulisevsky. *Movement Disorders Unit, Hospital Sant Pau, Barcelona, Spain*

**Background:** Impulse control disorders (ICDs) are frequently found in patients with PD treated with dopamine agonists. Despite their name, their relation with impulsivity is not well established.

**Objective:** To analyze the relationship between the presence and severity of impulse control disorders (ICDs) in PD and impulsivity.

**Methods:** Prospective study of 93 consecutive non-demented PD patients. ICDs were assessed using the Questionnaire for Impulsive-Compulsive Disorders (QUIP) and Minnesota Impulsive Disorders Interview (MIDI), and impulsivity using the Barratt Impulsiveness Scale (BIS-11) and commission errors in Conners' Continuous Performance Test II (CCPT).

**Results:** Thirty-five percent of patients (33/93) presented ICD. Younger age ( $p < 0.05$ ) and dopamine agonists use ( $p < 0.05$ ) were associated with presence of ICD but not to severity ( $p = 0.61$  and  $p = 0.72$  respectively). Impulsivity, either self-reported (BIS-11) or estimated by CCPT, did not differ between patients with ICD and without. However, in patients presenting ICD impulsivity measures correlated with ICD severity ( $p < 0.01$  for both measures). There was no relation between impulsivity and dopaminergic medication use. Dose of dopamine agonist was not associated with ICD. Other PD medications were also

not associated. Multivariate analysis confirmed significant association between ICD severity and impulsivity ( $p < 0.001$ ).

**Conclusion:** Age and dopamine agonist were associated with the presence of ICD, but not with their severity. Conversely, impulsivity was not associated with ICD presence but correlated with severity. This suggests a double dissociation, showing impulsivity as an independent variable explaining ICD severity in patients on treatment with dopamine agonists.

doi:10.1016/j.jns.2015.08.209

134

WFN15-1089

Movement Disorders 1

**Comparison between odor discrimination, substantia nigra echogenicity and nigrostriatal dopaminergic activity measured by 18F-PR04 pet in Parkinsonian syndromes**

C. Juri<sup>a</sup>, P. Venegas<sup>b</sup>, P. Chana<sup>c</sup>, V. Kramer<sup>d</sup>, R. Prusso<sup>d</sup>, H. Amaral<sup>d</sup>. <sup>a</sup>Neurology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; <sup>b</sup>Department of Neurology, Facultad de Medicina, Universidad de Chile, Santiago, Chile; <sup>c</sup>Department of Neurology, CETRAM, Facultad de Medicina, Universidad de Santiago de Chile, Santiago, Chile; <sup>d</sup>Nuclear Medicine, Positron Pharma Fundación A, Lopez Perez, Santiago, Chile

**Objective:** To evaluate the relationship between odor discrimination, substantia nigra echogenicity and nigrostriatal dopaminergic activity in patients with Parkinson's disease.

**Background:** Positron emission tomography for imaging dopaminergic pathways, transcranial substantia nigra (SN) echogenicity and odor discrimination are used as complementary tools for the diagnosis of PD. However there is a lack of information about the relationship between these three diagnostic methods for helping in the diagnosis of PD.

**Methods:** Twelve patients with PD according to established criteria were prospectively included. All subjects underwent a dynamic PET scan (Siemens mCT) for a duration of 2 h after bolus injection of  $165 \pm 15$  MBq (mean  $\pm$  SD) [<sup>18F</sup>]PR04.MZ. Data analysis using noninvasive Simplified Reference Tissue Model (SRTM) method and Cerebellum as reference was performed for estimation of binding potential in different brain regions. Odor discrimination was evaluated by using sniffing stick test (hyposmia  $< 7$  detections) and transcranial sonography of the SN was also conducted. Pathological echogenicity was considered as SN area more than  $0.20 \text{ cm}^2$ .

Study was approved by local and governmental authorities and participants signed informed consent.

**Results:** Age (mean  $\pm$  SD) was  $56.8 \pm 13.9$  years. Substantia nigra hyperechogenicity was found in 10 patients (SN area:  $28.8 \pm 14.2$ ). Hyposmia was observed in 6 cases ( $7.5 \pm 3$  odors). PET analyses showed dopaminergic depletion in 11 patients. Percentage of Posterior putamen depletion was  $66.0 \pm 29.2$ . Nine subjects with Dopaminergic depletion also exhibited SN hyperechogenicity. There was no relationship between SN area or olfaction detection and magnitude of dopaminergic depletion.

**Conclusions:** Evaluation of SN echogenicity and dopaminergic activity by 18FPR04.MZ PET are valuable tools in the diagnosis of PD. Larger studies are required to confirm these findings. SUPPORTED BY FONDECYT No. 11130534.

doi:10.1016/j.jns.2015.08.210